A Phase 2 interventional study of Axicabtagene ciloleucel and Cyclophosphamide in Follicular Lymphoma, Marginal Zone Lymphoma and Indolent Non-Hodgkin Lymphoma, sponsored by Kite, A Gilead Company. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Lymphoma, Follicular by Gilead Sciences — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Follicular · Gilead Sciences.
Among the 17 studies in Lymphoma, Follicular by Gilead Sciences, this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 2, and was the 15th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 17 studies in Lymphoma, Follicular by Gilead Sciences is open now. The open studies under Lymphoma, Follicular, anywhere →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 6
First in 1997; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 78 across the 16 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Kite, A Gilead Company, one of the names counted as Gilead Sciences. Under that name alone:
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Lymphoma, Follicular by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
After completing at least 60 months (FL participants) or at least 24 months (MZL participants) of assessments in this study since the initial axicabtagene ciloleucel infusion and after agreement by the Sponsor, participants will transition to a long-term follow-up (LTFU) study, KT-US-982-5968 where they will complete the remainder of the 15 year follow-up assessments.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsed or refractory (r/r) B-cell indolent non-Hodgkin lymphoma (iNHL) subtype of follicular lymphoma (FL) will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day for 3 days (Day -5 to Day -3). * A single infusion at a target dose of 2×10\^6 anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0.
Biological: Axicabtagene ciloleucel · Drug: Cyclophosphamide · Drug: Fludarabine
Participants with r/r B-cell iNHL subtype of marginal zone lymphoma (MZL) will receive the following treatment during the study: * A conditioning chemotherapy regimen of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day IV for 3 days (Day -5 to Day -3). * A single infusion at a target dose of 2×10\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.
Biological: Axicabtagene ciloleucel · Drug: Cyclophosphamide · Drug: Fludarabine
Administered intravenously
Also known as: Axi-cel, Yescarta®
Administered intravenously
Administered intravenously
Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment
OR:CR (complete metabolic response (CMR)+complete radiological response (CRR))+PR (partial MR response (PMR) +partial RR(PRR)).CMR: score 1(no uptake above background)/2(uptake≤mediastinum)/3(uptake \>mediastinum but ≤liver)with/without a residual mass on positron emission tomography 5-point scale;no new lesions,CRR:target nodes/nodal masses regressed to ≤1.5 cm in longest transverse diameter of lesion (LDi);no extralymphatic sites of disease;absent non-measured lesion(NMLs);organ enlargement regress to normal; no new sites;bone marrow normal by morphology.PMR:score 4(uptake moderately\>liver)/5(uptake markedly\>liver, new lesions) with reduced uptake compared with baseline and residual mass;no new lesions;responding disease at interim/residual disease at end of treatment.PRR:≥50% decrease in sum of product of diameters up to 6 target nodes and extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed by\>50% in length beyond normal. Percentages were rounded-off.
Time frame: Up to 85.6 months
Percentage of Participants With CR Per the Lugano Classification by Central Assessment
CR is defined in outcome measure (OM)#1. Percentages were rounded-off.
Time frame: Up to 85.6 months
ORR: Percentage of Participants With OR Per the Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy
OR was defined as percentage of participants with CR + PR per the Lugano Classification for participants with 3 or more lines of prior therapy. CR and PR are defined in OM#1. Percentages were rounded-off.
Time frame: Up to 85.6 months
Percentage of Participants With CR Per Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy
CR is defined as OM#1. Percentages were rounded-off.
Time frame: Up to 85.6 months
ORR: Percentage of Participants With OR Per the Lugano Classification by Investigator Assessment
OR was defined as percentage of participants with CR + PR per the Lugano Classification. CR and PR are defined in OM#1. Percentages were rounded-off.
Time frame: Up to 85.6 months
Percentage of Participants With Best Overall Response (BOR) Per the Lugano Classification by Central Assessment
BOR was defined as percentage of participants with CR, PR, stable disease(SD), disease progression(PD), non-evaluable(NE), undefined/no disease or not done as best response to treatment by the Lugano Classification. CR and PR defined in OM#1. SD/no metabolic response(NMR):score 4(uptake moderately greater than (\>) liver) or 5(uptake markedly\>liver and/ or new lesions) with no significant change in fluorodeoxyglucose(FDG) uptake compared to baseline(screening), at interim time point or end of treatment; no new sites of disease should be observed. PD:score 4(uptake moderately\>liver) or 5(uptake markedly\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. Not done:no assessment at time of analysis. Percentages were rounded off.
Time frame: Up to 85.6 months
Percentage of Participants With BOR Per the Lugano Classification by Investigator Assessment
BOR was defined as the percentage of participants with CR, PR, stable disease (SD), PD, NE (not evaluable) or not done as best response to treatment by the Lugano Classification. CR and PR are defined in OM#1. SD, PD and not done are defined in OM#6. Percentages were rounded off.
Time frame: Up to 85.6 months
Duration of Response (DOR) by Central Assessment
DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. CR and PR are defined in OM#1. PD is defined in OM#6. Kaplan-Meier (KM) estimates were used for analysis.
Time frame: Up to 85.6 months
DOR by Investigator Assessment
DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. Definitions for CR, PR are defined in OM#1. PD is defined in OM#6. KM estimates were used for analysis.
Time frame: Up to 85.6 months
Progression-free Survival (PFS) Per Lugano Classification by Central Assessment
PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.
Time frame: Up to 85.6 months
PFS Per Lugano Classification by Investigator Assessment
PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.
Time frame: Up to 85.6 months
Overall Survival (OS)
OS was defined as the time from axicabtagene ciloleucel infusion to the date of death. KM estimates were used for analysis.
Time frame: Up to 85.6
Time to Next Therapy
Time from axicabtagene ciloleucel infusion date to the start of the subsequent new lymphoma therapy or death from any cause. KM estimates were used for analysis.
Time frame: Up to 85.6 months
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
TEAE was defined as any adverse event with onset on or after the start of treatment. Percentages were rounded-off.
Time frame: Up to 85.6 months
Percentage of Participants With Increase in Laboratory Values Reported as Grade 3 or Higher
Percentages were rounded-off.
Time frame: Up to 85.6 months
Percentage of Participants With Decrease in Laboratory Values Reported as Grade 3 or Higher
Percentages were rounded-off.
Time frame: Up to 85.6 months
Percentage of Participants With Antibodies Against Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells
Time frame: Up to 85.6 months
Levels of Anti-CD19 CAR T Cells in Blood
Time frame: Day 7, Week 2, Week 4, Month 3, Month 6, Month 12, Month 18 and Month 24
Levels of Serum C-Reactive Protein (CRP)
Time frame: Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4
Levels of Serum Ferritin, Serum ICAM-1, Serum IL-2 R Alpha, Serum Perforin and Serum VCAM-1
Serum analytes: Serum Ferritin, Serum intercellular adhesion molecule-1 (ICAM-1), Serum interleukin-2 receptor (IL-2 R) alpha, Serum Perforin and Serum vascular cell adhesion molecule-1 (VCAM-1).
Time frame: Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4
Levels of Serum CXCL10, Serum Granzyme B, Serum IFN-gamma, Serum IL-1 RA, Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum TNF Alpha
Serum analytes: Serum CXCL10, Serum Granzyme B, Serum interferon (IFN)-gamma, Serum IL-1 receptor antagonist (RA), Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum tumor necrosis factor (TNF) Alpha.
Time frame: Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4
Participants were enrolled at study sites in the United States and France.
| Milestone | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Started | 127 | 31 |
| Completed | 0 | 0 |
| Not completed | 127 | 31 |
| Withdrew: Rollover to longterm follow-up study criteria | 61 | 15 |
| Withdrew: Death | 40 | 8 |
| Withdrew: Lost to follow-up | 13 | 2 |
| Withdrew: Subject withdrawal of consent from further follow-up | 7 | 3 |
| Withdrew: Reason not specified | 3 | 3 |
| Withdrew: Investigator decision | 3 | 0 |
OR:CR (complete metabolic response (CMR)+complete radiological response (CRR))+PR (partial MR response (PMR) +partial RR(PRR)).CMR: score 1(no uptake above background)/2(uptake≤mediastinum)/3(uptake \>mediastinum but ≤liver)with/without a residual mass on positron emission tomography 5-point scale;no new lesions,CRR:target nodes/nodal masses regressed to ≤1.5 cm in longest transverse diameter of lesion (LDi);no extralymphatic sites of disease;absent non-measured lesion(NMLs);organ enlargement regress to normal; no new sites;bone marrow normal by morphology.PMR:score 4(uptake moderately\>liver)/5(uptake markedly\>liver, new lesions) with reduced uptake compared with baseline and residual mass;no new lesions;responding disease at interim/residual disease at end of treatment.PRR:≥50% decrease in sum of product of diameters up to 6 target nodes and extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed by\>50% in length beyond normal. Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Objective Response Rate (ORR): Percentage of Participants With Objective Response Per the Lugano Classification by Central Assessment | 92 (86 to 96) | 69 (49 to 85) |
CR is defined in outcome measure (OM)#1. Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Percentage of Participants With CR Per the Lugano Classification by Central Assessment | 78 (70 to 85) | 52 (33 to 71) |
OR was defined as percentage of participants with CR + PR per the Lugano Classification for participants with 3 or more lines of prior therapy. CR and PR are defined in OM#1. Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| ORR: Percentage of Participants With OR Per the Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy | 91 (83 to 96) | 75 (51 to 91) |
CR is defined as OM#1. Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Percentage of Participants With CR Per Lugano Classification by Central Assessment Among Participants With 3 or More Lines of Prior Therapy | 79 (68 to 87) | 60 (36 to 81) |
OR was defined as percentage of participants with CR + PR per the Lugano Classification. CR and PR are defined in OM#1. Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| ORR: Percentage of Participants With OR Per the Lugano Classification by Investigator Assessment | 94 (88 to 97) | 77 (59 to 90) |
BOR was defined as percentage of participants with CR, PR, stable disease(SD), disease progression(PD), non-evaluable(NE), undefined/no disease or not done as best response to treatment by the Lugano Classification. CR and PR defined in OM#1. SD/no metabolic response(NMR):score 4(uptake moderately greater than (\>) liver) or 5(uptake markedly\>liver and/ or new lesions) with no significant change in fluorodeoxyglucose(FDG) uptake compared to baseline(screening), at interim time point or end of treatment; no new sites of disease should be observed. PD:score 4(uptake moderately\>liver) or 5(uptake markedly\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. Not done:no assessment at time of analysis. Percentages were rounded off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| CR | 78 (70 to 85) | 52 (33 to 71) |
| PR | 14 (9 to 21) | 17 (6 to 36) |
| SD | 4 (1 to 9) | 0 (0 to 12) |
| PD | 0 (0 to 3) | 3 (0 to 18) |
| Non-evaluable | 0 (0 to 3) | 0 (0 to 12) |
| Undefined/ No Disease | 1 (0 to 4) | 10 (2 to 27) |
| Not Done | 3 (1 to 8) | 17 (6 to 36) |
BOR was defined as the percentage of participants with CR, PR, stable disease (SD), PD, NE (not evaluable) or not done as best response to treatment by the Lugano Classification. CR and PR are defined in OM#1. SD, PD and not done are defined in OM#6. Percentages were rounded off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| CR | 79 (71 to 85) | 65 (45 to 81) |
| PR | 15 (9 to 22) | 13 (4 to 30) |
| SD | 2 (0 to 6) | 10 (2 to 26) |
| PD | 2 (0 to 6) | 3 (0 to 17) |
| NE | 0 (0 to 3) | 0 (0 to 11) |
| Not Done | 3 (1 to 8) | 10 (2 to 26) |
DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. CR and PR are defined in OM#1. PD is defined in OM#6. Kaplan-Meier (KM) estimates were used for analysis.
| months | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Duration of Response (DOR) by Central Assessment | 38.6 (NA to NA) | NA (8.2 to NA) |
DOR was defined only for participants who experienced an OR (CR and PR) and was the time from the first objective response to disease progression or disease-related death, whichever came first. Definitions for CR, PR are defined in OM#1. PD is defined in OM#6. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| DOR by Investigator Assessment | 60.4 (36.6 to NA) | NA (13.9 to NA) |
PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Progression-free Survival (PFS) Per Lugano Classification by Central Assessment | 40.2 (28.9 to NA) | 18.3 (12.1 to NA) |
PFS was defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause. PD is defined in OM 6. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| PFS Per Lugano Classification by Investigator Assessment | 58.2 (30.9 to NA) | NA (12.4 to NA) |
OS was defined as the time from axicabtagene ciloleucel infusion to the date of death. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Time from axicabtagene ciloleucel infusion date to the start of the subsequent new lymphoma therapy or death from any cause. KM estimates were used for analysis.
| months | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Time to Next Therapy | NA (37.8 to NA) | NA (12.1 to NA) |
TEAE was defined as any adverse event with onset on or after the start of treatment. Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 99 | 100 |
Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Grade 3 or Higher Increase in Hemoglobin (mmol/L) | 0 | 0 |
| Grade 3 or Higher Increase in Leukocytes (10^9/L) | 1 | 0 |
| Grade 3 or Higher Increase in Lymphocytes (10^9/L) | 0 | 0 |
| Grade 3 or Higher Increase in Alanine Aminotransferase (U/L) | 6 | 21 |
| Grade 3 or Higher Increase in Alkaline Phosphatase (U/L) | 0 | 4 |
| Grade 3 or Higher Increase in Aspartate Aminotransferase (U/L) | 4 | 11 |
| Grade 3 or Higher Increase in Bilirubin (umol/L) | 4 | 11 |
| Grade 3 or Higher Increase in Calcium (mmol/L) | 1 | 0 |
| Grade 3 or Higher Increase in Creatinine (umol/L) | 1 | 0 |
| Grade 3 or Higher Increase in Direct Bilirubin (umol/L) | 2 | 11 |
| Grade 3 or Higher Increase in Glucose (mmol/L) | 9 | 21 |
| Grade 3 or Higher Increase in Magnesium (mmol/L) | 3 | 4 |
| Grade 3 or Higher Increase in Potassium (mmol/L) | 1 | 0 |
| Grade 3 or Higher Increase in Sodium (mmol/L) | 0 | 0 |
| Grade 3 or Higher Increase in Urate (mmol/L) | 13 | 25 |
Percentages were rounded-off.
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Grade 3 or Higher Decrease in Hemoglobin (mmol/L) | 33 | 39 |
| Grade 3 or Higher Decrease in Leukocytes (10^9/L) | 94 | 93 |
| Grade 3 or Higher Decrease in Lymphocytes (10^9/L) | 99 | 100 |
| Grade 3 or Higher Decrease in Neutrophils (10^9/L) | 92 | 96 |
| Grade 3 or Higher Decrease in Platelets (10^9/L) | 35 | 32 |
| Grade 3 or Higher Decrease in Albumin (g/L) | 2 | 4 |
| Grade 3 or Higher Decrease in Calcium (mmol/L) | 10 | 7 |
| Grade 3 or Higher Decrease in Glucose (mmol/L) | 0 | 0 |
| Grade 3 or Higher Decrease in Magnesium (mmol/L) | 0 | 0 |
| Grade 3 or Higher Decrease in Phosphate (mmol/L) | 23 | 39 |
| Grade 3 or Higher Decrease in Potassium (mmol/L) | 4 | 7 |
| Grade 3 or Higher Decrease in Sodium (mmol/L) | 9 | 18 |
| percentage of participants | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Percentage of Participants With Antibodies Against Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells | 0 | 0 |
| cells/μL | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Day 7 | 101.49 ± 220.01 | 120.07 ± 394.91 |
| Week 2 | 41.45 ± 63.65 | 90.76 ± 128.63 |
| Week 4 | 7.52 ± 19.85 | 14.03 ± 23.43 |
| Month 3 | 0.78 ± 1.91 | 0.52 ± 0.51 |
| Month 6 | 3.49 ± 28.89 | 0.68 ± 1.90 |
| Month 12 | 1.00 ± 5.65 | 0.23 ± 0.43 |
| Month 18 | 0.47 ± 1.51 | 0.42 ± 0.77 |
| Month 24 | 0.36 ± 0.84 | 0.88 ± 2.09 |
| mg/L | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Serum CRP on Baseline | 22.36 ± 40.60 | 19.87 ± 28.62 |
| Serum CRP on Day 0 | 29.30 ± 47.35 | 32.94 ± 42.50 |
| Serum CRP on Day 3 | 72.50 ± 91.76 | 66.73 ± 92.82 |
| Serum CRP on Day 7 | 59.45 ± 79.24 | 77.79 ± 91.86 |
| Serum CRP on Week 2 | 9.07 ± 19.70 | 13.59 ± 42.20 |
| Serum CRP on Week 4 | 7.84 ± 33.76 | 9.86 ± 43.46 |
Serum analytes: Serum Ferritin, Serum intercellular adhesion molecule-1 (ICAM-1), Serum interleukin-2 receptor (IL-2 R) alpha, Serum Perforin and Serum vascular cell adhesion molecule-1 (VCAM-1).
| ng/L | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Serum Ferritin on Baseline | 330.54 ± 398.03 | 207.63 ± 218.42 |
| Serum Ferritin on Day 0 | 503.99 ± 502.07 | 398.49 ± 337.82 |
| Serum Ferritin on Day 3 | 541.51 ± 457.18 | 487.39 ± 414.90 |
| Serum Ferritin on Day 7 | 779.75 ± 782.98 | 1820.38 ± 4837.56 |
| Serum Ferritin on Week 2 | 741.76 ± 787.70 | 959.49 ± 1546.07 |
| Serum Ferritin on Week 4 | 528.83 ± 605.94 | 478.47 ± 459.54 |
| Serum ICAM-1 on Baseline | 876.99 ± 833.80 | 709.71 ± 430.14 |
| Serum ICAM-1 on Day 0 | 834.87 ± 854.35 | 642.60 ± 365.92 |
| Serum ICAM-1 on Day 3 | 964.45 ± 904.79 | 792.47 ± 621.84 |
| Serum ICAM-1 on Day 7 | 924.99 ± 846.56 | 934.02 ± 618.96 |
| Serum ICAM-1 on Week 2 | 695.15 ± 605.03 | 696.77 ± 438.71 |
| Serum ICAM-1 on Week 4 | 671.32 ± 656.46 | 614.92 ± 487.67 |
| Serum IL-2 R alpha on Baseline | 8.52 ± 12.15 | 5.62 ± 7.50 |
| Serum IL-2 R alpha on Day 0 | 8.39 ± 9.10 | 4.91 ± 4.12 |
| Serum IL-2 R alpha on Day 3 | 9.96 ± 11.53 | 7.31 ± 5.68 |
| Serum IL-2 R alpha on Day 7 | 14.42 ± 15.10 | 19.78 ± 20.82 |
| Serum IL-2 R alpha on Week 2 | 7.16 ± 8.27 | 10.40 ± 12.26 |
| Serum IL-2 R alpha on Week 4 | 3.39 ± 3.34 | 4.02 ± 3.67 |
| Serum Perforin on Baseline | 13.26 ± 7.20 | 13.58 ± 18.33 |
| Serum Perforin on Day 0 | 2.56 ± 1.85 | 3.30 ± 9.11 |
| Serum Perforin on Day 3 | 3.87 ± 3.36 | 4.71 ± 13.53 |
| Serum Perforin on Day 7 | 8.49 ± 10.54 | 6.60 ± 7.99 |
| Serum Perforin on Week 2 | 8.06 ± 6.90 | 6.01 ± 6.77 |
| Serum Perforin on Week 4 | 14.56 ± 11.92 | 12.32 ± 12.08 |
| Serum VCAM-1 on Baseline | 1499.37 ± 1637.98 | 1282.81 ± 1232.76 |
| Serum VCAM-1 on Day 0 | 1182.41 ± 1166.58 | 931.58 ± 709.94 |
| Serum VCAM-1 on Day 3 | 1213.84 ± 962.38 | 1044.96 ± 870.11 |
| Serum VCAM-1 on Day 7 | 1224.58 ± 1069.13 | 1209.51 ± 780.31 |
| Serum VCAM-1 on Week 2 | 891.64 ± 726.10 | 977.88 ± 919.47 |
| Serum VCAM-1 on Week 4 | 981.67 ± 879.87 | 930.89 ± 885.51 |
Serum analytes: Serum CXCL10, Serum Granzyme B, Serum interferon (IFN)-gamma, Serum IL-1 receptor antagonist (RA), Serum IL-2, Serum IL-6, Serum IL-7, Serum IL-8, Serum IL-10, Serum IL-15, Serum tumor necrosis factor (TNF) Alpha.
| pg/mL | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) |
|---|---|---|
| Serum CXCL10 on Baseline | 466.32 ± 339.00 | 634.56 ± 539.17 |
| Serum CXCL10 on Day 0 | 499.16 ± 334.85 | 763.99 ± 569.42 |
| Serum CXCL10 on Day 3 | 712.31 ± 543.76 | 962.96 ± 611.23 |
| Serum CXCL10 on Day 7 | 841.62 ± 572.80 | 1630.98 ± 563.40 |
| Serum CXCL10 on Week 2 | 474.45 ± 371.95 | 798.28 ± 631.80 |
| Serum CXCL10 on Week 4 | 623.87 ± 535.45 | 964.92 ± 640.57 |
| Serum Granzyme B on Baseline | 3.58 ± 9.68 | 121.49 ± 623.76 |
| Serum Granzyme B on Day 0 | 2.95 ± 7.86 | 46.36 ± 234.23 |
| Serum Granzyme B on Day 3 | 6.53 ± 11.03 | 74.28 ± 348.53 |
| Serum Granzyme B on Day 7 | 76.29 ± 494.66 | 52.87 ± 68.63 |
| Serum Granzyme B on Week 2 | 2.73 ± 5.67 | 27.21 ± 102.65 |
| Serum Granzyme B on Week 4 | 3.14 ± 5.15 | 17.00 ± 39.90 |
| Serum IFN-gamma on Baseline | 9.25 ± 7.17 | 30.29 ± 83.67 |
| Serum IFN-gamma on Day 0 | 11.20 ± 16.17 | 54.04 ± 140.40 |
| Serum IFN-gamma on Day 3 | 157.13 ± 326.44 | 292.67 ± 531.54 |
| Serum IFN-gamma on Day 7 | 139.82 ± 359.84 | 674.34 ± 792.31 |
| Serum IFN-gamma on Week 2 | 25.98 ± 48.82 | 27.16 ± 37.43 |
| Serum IFN-gamma on Week 4 | 23.96 ± 37.04 | 56.72 ± 108.10 |
| Serum IL-1 RA on Baseline | 584.66 ± 400.47 | 627.95 ± 467.39 |
| Serum IL-1 RA on Day 0 | 677.50 ± 743.22 | 960.41 ± 1342.30 |
| Serum IL-1 RA on Day 3 | 703.79 ± 772.95 | 848.20 ± 757.98 |
| Serum IL-1 RA on Day 7 | 1125.80 ± 1316.88 | 2492.85 ± 2895.93 |
| Serum IL-1 RA on Week 2 | 591.72 ± 764.19 | 854.68 ± 1693.69 |
| Serum IL-1 RA on Week 4 | 653.88 ± 1197.23 | 1106.94 ± 1935.55 |
| Serum IL-2 on Baseline | 1.03 ± 0.53 | 1.12 ± 0.90 |
| Serum IL-2 on Day 0 | 1.20 ± 1.22 | 1.16 ± 1.09 |
| Serum IL-2 on Day 3 | 8.01 ± 13.08 | 12.43 ± 34.49 |
| Serum IL-2 on Day 7 | 1.67 ± 2.55 | 2.99 ± 3.78 |
| Serum IL-2 on Week 2 | 0.95 ± 0.48 | 0.93 ± 0.18 |
| Serum IL-2 on Week 4 | 0.95 ± 0.50 | 1.10 ± 1.06 |
| Serum IL-6 on Baseline | 2.71 ± 2.90 | 5.08 ± 8.11 |
| Serum IL-6 on Day 0 | 2.42 ± 2.27 | 4.14 ± 5.39 |
| Serum IL-6 on Day 3 | 59.30 ± 185.89 | 103.93 ± 281.61 |
| Serum IL-6 on Day 7 | 67.49 ± 197.95 | 206.75 ± 282.31 |
| Serum IL-6 on Week 2 | 20.01 ± 92.15 | 33.00 ± 66.24 |
| Serum IL-6 on Week 4 | 31.02 ± 122.14 | 58.84 ± 169.85 |
| Serum IL-7 on Baseline | 15.99 ± 7.89 | 15.30 ± 7.13 |
| Serum IL-7 on Day 0 | 27.65 ± 9.62 | 28.31 ± 10.15 |
| Serum IL-7 on Day 3 | 26.50 ± 10.22 | 27.24 ± 10.82 |
| Serum IL-7 on Day 7 | 23.42 ± 11.28 | 23.28 ± 11.69 |
| Serum IL-7 on Week 2 | 27.25 ± 14.13 | 26.38 ± 16.52 |
| Serum IL-7 on Week 4 | 18.45 ± 8.92 | 20.30 ± 10.52 |
| Serum IL-8 on Baseline | 13.59 ± 15.09 | 13.71 ± 9.11 |
| Serum IL-8 on Day 0 | 21.12 ± 33.53 | 42.71 ± 129.39 |
| Serum IL-8 on Day 3 | 60.27 ± 126.84 | 80.86 ± 154.41 |
| Serum IL-8 on Day 7 | 45.79 ± 86.38 | 37.47 ± 30.74 |
| Serum IL-8 on Week 2 | 16.08 ± 17.14 | 41.41 ± 117.98 |
| Serum IL-8 on Week 4 | 20.36 ± 68.72 | 18.90 ± 13.80 |
| Serum IL-10 on Baseline | 2.85 ± 3.76 | 5.11 ± 6.72 |
| Serum IL-10 on Day 0 | 1.93 ± 2.29 | 1.89 ± 2.18 |
| Serum IL-10 on Day 3 | 9.34 ± 17.60 | 7.39 ± 10.14 |
| Serum IL-10 on Day 7 | 15.01 ± 34.55 | 20.32 ± 20.70 |
| Serum IL-10 on Week 2 | 2.06 ± 4.64 | 3.42 ± 4.88 |
| Serum IL-10 on Week 4 | 1.10 ± 1.31 | 1.65 ± 2.08 |
| Serum IL-15 on Baseline | 2.70 ± 2.69 | 2.59 ± 1.42 |
| Serum IL-15 on Day 0 | 31.06 ± 13.55 | 33.89 ± 16.32 |
| Serum IL-15 on Day 3 | 35.27 ± 19.66 | 43.43 ± 37.40 |
| Serum IL-15 on Day 7 | 18.73 ± 9.77 | 25.22 ± 15.38 |
| Serum IL-15 on Week 2 | 10.30 ± 5.90 | 12.92 ± 8.28 |
| Serum IL-15 on Week 4 | 4.98 ± 3.52 | 7.41 ± 5.21 |
| Serum TNF Alpha on Baseline | 7.26 ± 7.87 | 6.73 ± 7.86 |
| Serum TNF Alpha on Day 0 | 3.32 ± 2.62 | 3.08 ± 1.68 |
| Serum TNF Alpha on Day 3 | 3.95 ± 2.68 | 4.90 ± 4.59 |
| Serum TNF Alpha on Day 7 | 3.93 ± 3.10 | 5.97 ± 4.09 |
| Serum TNF Alpha on Week 2 | 2.84 ± 6.01 | 2.74 ± 2.30 |
| Serum TNF Alpha on Week 4 | 2.36 ± 1.65 | 3.03 ± 2.13 |
Collected over Up to 85.6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axicabtagene Ciloleucel: Follicular Lymphoma | 36/127 (28.3%) | 65/124 (52.4%) | 123/124 (99.2%) |
| Axicabtagene Ciloleucel: Marginal Zone Lymphoma | 8/31 (25.8%) | 19/28 (67.9%) | 28/28 (100%) |
| Axicabtagene Ciloleucel: Retreatment (FL) | 5/14 (35.7%) | 5/14 (35.7%) | 13/14 (92.9%) |
| Axicabtagene Ciloleucel: Retreatment (MZL) | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Event | Axicabtagene Ciloleucel: Follicular Lymphoma | Axicabtagene Ciloleucel: Marginal Zone Lymphoma | Axicabtagene Ciloleucel: Retreatment (FL) | Axicabtagene Ciloleucel: Retreatment (MZL) |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 3/124 | 0/28 | 0/14 | 1/2 |
| PyrexiaGeneral disorders | 16/124 | 6/28 | 0/14 | 0/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/124 | 3/28 | 0/14 | 0/2 |
| PneumoniaInfections and infestations | 10/124 | 3/28 | 0/14 | 0/2 |
| EncephalopathyNervous system disorders | 8/124 | 3/28 | 0/14 | 0/2 |
| SomnolenceNervous system disorders | 2/124 | 3/28 | 0/14 | 0/2 |
| HypotensionVascular disorders | 2/124 | 3/28 | 0/14 | 0/2 |
| Atrial fibrillationCardiac disorders | 0/124 | 2/28 | 0/14 | 0/2 |
| Parainfluenzae virus infectionInfections and infestations | 0/124 | 0/28 | 1/14 | 0/2 |
| Progressive multifocal leukoencephalopathyInfections and infestations | 0/124 | 0/28 | 1/14 | 0/2 |
| Event | Axicabtagene Ciloleucel: Follicular Lymphoma | Axicabtagene Ciloleucel: Marginal Zone Lymphoma | Axicabtagene Ciloleucel: Retreatment (FL) | Axicabtagene Ciloleucel: Retreatment (MZL) |
|---|---|---|---|---|
| Sinus tachycardiaCardiac disorders | 41/124 | 8/28 | 3/14 | 2/2 |
| ConstipationGastrointestinal disorders | 35/124 | 7/28 | 1/14 | 2/2 |
| NauseaGastrointestinal disorders | 45/124 | 17/28 | 5/14 | 2/2 |
| FatigueGeneral disorders | 50/124 | 15/28 | 3/14 | 2/2 |
| PyrexiaGeneral disorders | 99/124 | 24/28 | 8/14 | 2/2 |
| HeadacheNervous system disorders | 55/124 | 12/28 | 5/14 | 2/2 |
| HypotensionVascular disorders | 59/124 | 15/28 | 3/14 | 1/2 |
| AnaemiaBlood and lymphatic system disorders | 46/124 | 14/28 | 2/14 | 1/2 |
| Oedema peripheralGeneral disorders | 10/124 | 4/28 | 1/14 | 1/2 |
| PainGeneral disorders | 17/124 | 3/28 | 0/14 | 1/2 |
The Safety Analysis Set was defined as all participants treated with any dose of study drug.
| Age, Categorical(Participants) | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 86 | 15 | 101 |
| >=65 years | 38 | 13 | 51 |
| Age, Continuous(years) | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) | Total |
|---|---|---|---|
| Mean | 59 ± 9.9 | 63 ± 9.6 | 60.0 ± 10.0 |
| Sex: Female, Male(Participants) | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) | Total |
|---|---|---|---|
| Female | 51 | 15 | 66 |
| Male | 73 | 13 | 86 |
| Ethnicity (NIH/OMB)(Participants) | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 3 | 9 |
| Not Hispanic or Latino | 118 | 24 | 142 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) | Total |
|---|---|---|---|
| Race — White | 115 | 25 | 140 |
| Race — Black or African American | 4 | 2 | 6 |
| Race — Other or More Than One Race | 3 | 1 | 4 |
| Race — Asian | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Axicabtagene Ciloleucel (Follicular Lymphoma) | Axicabtagene Ciloleucel (Marginal Zone Lymphoma) | Total |
|---|---|---|---|
| United States | 114 | 28 | 142 |
| France | 10 | 0 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Jun 2017 to primary completion in Dec 2024, 90 months.
Results were first posted in Dec 2025, 1 year after primary completion.
Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 90 months is above that.
Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axicabtagene ciloleucel